In HCC, adoptive cell therapies primarily target GPC3, with multiple related studies progressing into phase I clinical trials (Rochigneux et al., 2021; Zhu et al., 2018b; Zheng et al., 2022). This evidence concerns the gene GPC3 and hepatocellular carcinoma.